These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Pagliaro L; Daliani D; Amato R; Tu SM; Jones D; Smith T; Logothetis C; Millikan R Cancer; 2000 Aug; 89(3):615-8. PubMed ID: 10931461 [TBL] [Abstract][Full Text] [Related]
69. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. Di Lorenzo G; Cartenì G; Autorino R; Bruni G; Tudini M; Rizzo M; Aieta M; Gonnella A; Rescigno P; Perdonà S; Giannarini G; Pignata S; Longo N; Palmieri G; Imbimbo C; De Laurentiis M; Mirone V; Ficorella C; De Placido S J Clin Oncol; 2009 Sep; 27(27):4469-74. PubMed ID: 19652053 [TBL] [Abstract][Full Text] [Related]
70. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib]. Xie XD; Piao Y; Liu ZZ Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872 [No Abstract] [Full Text] [Related]
71. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Takenaka A; Inoue TA; Fujisawa M BJU Int; 2010 Dec; 106(11):1643-7. PubMed ID: 20553261 [TBL] [Abstract][Full Text] [Related]
72. Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave-Roussy. Droz JP; Theodore C; Ghosn M; Lupera H; Piot G; De Forges A; Klink M; Rouesse J; Amiel JL Semin Surg Oncol; 1988; 4(2):97-9. PubMed ID: 3393780 [TBL] [Abstract][Full Text] [Related]
73. Axitinib in the treatment of metastatic renal cell carcinoma. Ho TH; Jonasch E Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199 [TBL] [Abstract][Full Text] [Related]
74. Evaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases. Ishihara H; Kondo T; Tanabe K Ther Apher Dial; 2017 Aug; 21(4):414-416. PubMed ID: 28593648 [No Abstract] [Full Text] [Related]
75. [The introduction of targeted drugs]. Bergmann L; Miller K Onkologie; 2010; 33 Suppl 1():1. PubMed ID: 20164667 [No Abstract] [Full Text] [Related]
76. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. Schöffski P; Garcia JA; Stadler WM; Gil T; Jonasch E; Tagawa ST; Smitt M; Yang X; Oliner KS; Anderson A; Zhu M; Kabbinavar F BJU Int; 2011 Sep; 108(5):679-86. PubMed ID: 21156020 [TBL] [Abstract][Full Text] [Related]
77. The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma. Nagaya N; Kanayama M; Nagata M; Horie S Intern Med; 2018 Sep; 57(18):2695-2700. PubMed ID: 29709937 [TBL] [Abstract][Full Text] [Related]
78. Treatment of concurrent metastatic renal cell carcinoma and chronic myelogenous leukemia--easier said than done? A case report. Al-Najjar F; Jarkowski A J Oncol Pharm Pract; 2011 Dec; 17(4):436-9. PubMed ID: 20847086 [TBL] [Abstract][Full Text] [Related]
79. Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer. Wilding G; Grindey G; Munshi N; Seitz D; Einhorn L Invest New Drugs; 1993; 11(2-3):203-5. PubMed ID: 8262732 [No Abstract] [Full Text] [Related]
80. High-dose cimetidine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group study. Inhorn L; Williams SD; Nattam S; Stephens D Am J Clin Oncol; 1992 Apr; 15(2):157-9. PubMed ID: 1553905 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]